We Look Forward To Seeing You At The Westin San Diego Gaslamp Quarter!
SPONSORS
PREMIER SPONSOR
Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.
MAJOR SPONSORS
Genentech
Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA), and other retinal diseases.
Lenz Therapeutics
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision, proudly based in San Diego. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia.
SUPPORTING SPONSORS
Adverum Biotechnologies
Adverum is pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases. Adverum’s lead program, Ixoberogene soroparvovec (Ixo-vec), is designed to be administered as a one-time IVT injection in the physician’s office, deliver long-term efficacy, reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and improve vision outcomes for patients with wet AMD.
Stuart Therapeutics
Stuart Therapeutics, Inc. is a clinical-stage drug platform company developing new therapies to treat a broad array of ocular conditions with a completely novel approach – healing through the restoration of disease-damaged collagen. The company’s PolyCol™ collagen mimetic peptide (CMP) technology platform is the first drug class to selectively target and heal specific areas of collagen damage implicated in trauma and disease where there is significant unmet need, including dry eye disease, corneal wound healing, glaucoma, dry AMD and myopia. The lead candidate on the PolyCol platform, ST-100, has demonstrated fast-acting resolution of dry eye signs and symptoms, signaling the opportunity to disrupt this $9.1 billion market and build an ocular surface franchise. The Stuart Therapeutics team includes executive leaders with extensive startup, early stage and large public company experience, as well as scientific advisors with deep expertise ophthalmic medicine and research. Headquartered in Stuart, Florida, Stuart Therapeutics is a privately held company with strong investor support, including InFocus Capital and the University of Wisconsin’s Alumni Research Foundation (WARF) and partnerships including Glaukos, Aju Pharm Co, Ora, Vanderbilt University and the University of Rochester. To learn more visit stuarttherapeutics.com and connect on LinkedIn.
INNOVATION SPONSORS
4DMT
4D Molecular Therapeutics (4DMT) is a late-stage biotechnology company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our lead program 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, safe, intravitreal injection. Our second core program is 4D-710, which is the first known genetic medicine to demonstrate, in the lungs of people with cystic fibrosis (CF), successful delivery and expression of the CFTR transgene and initial clinical activity signals after aerosol delivery of a gene therapy.
Apellis
Apellis is a global biopharmaceutical company that leverages courageous science, creativity, and compassion to lead the development of therapies that target the complement system. Apellis is committed to addressing the unmet medical needs of patients and eye care professionals worldwide, with the goal of slowing progression of Geographic Atrophy.
Astellas Pharma
Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., with its headquarters located in Northbrook, Illinois. More than 3,000 Astellas employees are based in the United States. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
Cloudbreak Pharma
We are a clinical stage global biotechnology company developing ophthalmic drugs for chronic eye diseases which are often with few treatment options. Our broad pipeline was developed by in-house scientists with the experience and expertise to identify new targeted mechanisms of action and craft formulations that are amenable to topical ocular delivery. Our deep understanding of ophthalmic disease pathogenesis and extensive scientific know-how led us to our lead pipeline candidate, CBT-001 – an investigational eye drop treatment with the potential to slow or stop progression of pterygium, a highly underdiagnosed and undertreated disease with no approved drug therapy.
Neurotech Pharmaceuticals
Neurotech Pharmaceuticals, Inc. is a private biotech company focused on developing transformative therapies for chronic eye diseases. The core platform technology, Encapsulated Cell Therapy (ECT), is a first-in-class drug delivery platform designed to slow the progression of Macular Telangiectasia Type 2 (MacTel) and other chronic eye diseases. ENCELTOTM (revakinagene taroretcel-lwey) is approved in the United States for the treatment of adults with idiopathic Macular Telangiectasia Type 2 (MacTel).
Novaliq
Novaliq is a privately held biopharmaceutical company focusing on the development of first- and best-in-class ocular therapeutics, headquartered in Heidelberg, Germany with an office in Cambridge, MA, USA.
Novaliq developed EyeSol®, a novel drug category of water-free topical eyecare therapies. Two FDA approved EyeSol® dry eye disease drugs - Miebo™ and Vevye™ - are transforming the standard of care in the U.S. These products are successfully partnered in all major countries globally, with additional approvals in the EU, UK, China or Canada, while regulatory reviews in other key countries are ongoing.
Today’s pipeline extends beyond dry eye disease, providing multiple ophthalmic opportunities in general ophthalmology and retina therapies.
Novaliq focusses on two novel EyeSol®-based topical therapies: A clinical proof-of-principle trial study in non-infectious uveitis using topical tacrolimus in EyeSol® is expected to start in Q1 2026 and is successfully financed. Meanwhile, the discovery program screening APIs in EyeSol® to treat non-proliferative diabetic retinopathy has made significant progress and identified promising targets and molecules.
Novaliq’s vision is to accelerate growth and pipeline expansion to build a leading biopharma company. We are actively seeking new partnerships, collaborations, and investors to join us on this journey. Together, we aim to accelerate breakthrough development opportunities and bring Novaliq to the next level.
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI) is Ocular’s leading investigational candidate for retinal diseases, based on its proprietary ELUTYX™ (bioresorbable hydrogel) technology combined with potent tyrosine kinase inhibitor (TKI), axitinib. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and has potential applications across other retinal diseases such as non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME).
Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
Ray Therapeutics
Ray Therapeutics Inc (RayTx) is a late-stage preclinical Bay Area biotechnology company pioneering the first-to-market precision optogenetic therapy for vision restoration that is highly active in ambient lighting (and will not require light-enhancing goggles). Our studies have shown for the first time that our proprietary ChRown optogenetic protein can restore high levels of visual acuity, contrast sensitivity and visual field.
RayTx lead asset, RTx-015, is expected to address the huge unmet medical in people suffering from many forms of retinal blindness (independent of the underlying genetic cause), including those with advanced age-related macular degeneration. RayTx has partnered with a world-leading AAV gene therapy manufacturer is utilizing their proprietary commercial manufacturing process and analytics to maximally de-risk clinical development. RayTx anticipates clinical trials will begin by the end of 2023 in our initial indication, retinitis pigmentosa.
REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.
MEDIA PARTNERS
